Roots Analysis

AUGUST 31, 2023

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. For example, people affected by phenylketonuria must avoid consuming food containing phenylalanine amino acid.

Genomics 40

Genomics Genome Genetics Gene 40

XTalks

APRIL 15, 2021

Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. The reverse could also be true whereby the development of coronary artery disease may impact heart rate. HFrEF vs. HFpEF.

Development 98

Development Drugs Genomics Genome 98

Delveinsight

DECEMBER 13, 2020

Due to hepatitis C, most people develop cirrhosis, or scarring of the liver, before liver cancer; about 5–25% of patients with chronic hepatitis C develop cirrhosis over 10–20 years. Research and development in Hepatitis. 2b) was developed to maintain a steady level of an active drug and reduce the frequency of administration.

Genotype 52

Genotype FDA Approval DNA Drugs 52

pharmaphorum

JANUARY 18, 2023

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. First, start co-development with participants early on in the process. Building technology collaboratively and developing new methodologies for participant-centred design is the answer. Giving participants something in return.

Genetic Disease 97

Genetic Disease Genetics Research Genomics 97

XTalks

APRIL 24, 2023

To achieve this, Medpace works in multi-disciplinary teams of experts to jointly develop and execute advanced therapy protocols. For rare disease studies where there is little or no clinical trial experience, outcome assessments would have to be validated within a clinical development program.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

NOVEMBER 2, 2020

(NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today provided an update on its landmark ONWARD Phase 3 pivotal trial. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions.

Trials 52

Trials Genotype Marketing Production 52

XTalks

MARCH 3, 2021

BridgeBio is dedicated to developing therapies for genetic diseases with unmet needs. BridgeBio said in an announcement that the novel therapy was developed based on “BridgeBio’s commitment to developing a treatment for MoCD Type A in collaboration with the experts and families in the MoCD Type A community.”

FDA Approval 64

FDA Approval Genotype Clinical Trials Clinical Trials 64

The Pharma Data

MARCH 7, 2022

The IGA results in the equivalent genotype (genetic make-up) and short-hair coat trait seen in some conventionally bred cattle, known as a “slick” coat. This is the FDA’s first low-risk determination for enforcement discretion for an IGA in an animal for food use. Solomon, D.V.M., director of the FDA’s Center for Veterinary Medicine. “It

Genomics 52

Genomics Genome Production Marketing 52

The Pharma Data

APRIL 14, 2021

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. FOSTER CITY, Calif.–(BUSINESS

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52

The Pharma Data

SEPTEMBER 2, 2021

in the US and Canada) to develop and commercialise Lynparza; with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to develop and commercialise Enhertu and Dato-DXd, and with HUTCHMED to develop and commercialise savolitinib. AstraZeneca is collaborating with MSD (Merck & Co., Lead author. Abstract title. Garassino, MC.

Trials 52

Trials Medicine Antibody Clinical Trials 52

The Pharma Data

APRIL 7, 2021

Today’s approval is the culmination of a multi-year development program and validates the clinical benefit of this important treatment in metastatic TNBC,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

MARCH 25, 2021

In addition to multiple ongoing studies of SG in triple-negative breast cancer, it is being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/HER 2-negative metastatic breast cancer, and metastatic non-small cell lung cancer, either as a monotherapy or in combination with other agents.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52